KN-510

KN-510 is a small molecule drug that functions as a blocker of SLC25A20, also known as the carnitine-acylcarnitine carrier. It is being developed primarily for oncology indications, with its main mechanism involving inhibition of mitochondrial fatty acid transport via SLC25A20 blockade. This disrupts energy metabolism in cancer cells and may have antitumor effects. The drug was initially developed by New Cancer Cure-Bio Co.,Ltd., and has reached Phase 1 clinical trials for advanced malignant solid neoplasms. There is also preclinical development activity in pancreatic cancer[1][7]. Patent literature suggests omeprazole may be used as the active agent in this context, acting as an inhibitor of the carnitine acylcarnitine carrier[7].